Blog 

There are encouraging signals, but no blanket answer for home masks

Photobiomodulation (PBM) describes biological responses to light. The label covers different sources and exposure conditions; it is not a single melasma treatment.

A 2024 integrative review brought together laboratory, animal and clinical research. It described promising findings but called for stronger clinical trials. Its evidence mix matters: a reduction in melanin in cultured cells is not the same as sustained improvement in facial melasma. The review also includes different wavelengths and both LEDs and low-power lasers. [1]

There is human melasma research, so “no studies exist” would be inaccurate. A 2018 LED study reported improvement in women with darker skin types. However, the accessible publisher abstract describes groups assigned by skin type, with both receiving LED treatment; it does not describe a sham or untreated comparison. Full methods were not accessible for this article. This supports further investigation, rather than a claim that an unspecified home mask works. [3]

The two unresolved questions are separate: does a particular exposure improve diagnosed melasma, and can that exposure aggravate pigmentation in the intended users? A positive result for one outcome does not settle the other. Neither “all red light worsens melasma” nor “red light cannot worsen pigment” follows from the evidence reviewed here.

Start with the diagnosis, not the word “spots”

Melasma is a pigmentary condition, not a catch-all name for uneven color. A dermatologist can distinguish it from another cause of discoloration, sometimes using closer examination or additional testing. Improvement in an aging-related dark-spot study cannot automatically be applied to melasma. [4]

When reading a study or device claim, look for an explicit melasma diagnosis. “Brighter skin,” “more even tone” and general spot counts do not establish that the study measured melasma severity. Ask whether it used a melasma-specific assessment, such as the modified Melasma Area and Severity Index (mMASI), alongside consistent photographs and follow-up. This is an evidence checklist, not a way to diagnose yourself.

Red, blue and broad visible light answer different questions

The blue-versus-red finding and the high-fluence red safety findings should not be flattened into a universal color rule. They examine different exposures and populations. Red is not ultraviolet (UV), but being outside UV does not by itself prove that pigmentation cannot change.

A combination treatment cannot prove the contribution of the LED

A 2026 split-face study compared PBM plus cord blood–derived platelet-rich plasma with PBM plus a picosecond laser. All participants received whole-face PBM, described in the methods as a blend of 590- and 830-nm light. Both combinations improved melasma severity, but there was no LED-free or LED-only arm to isolate the PBM contribution. This was neither a red-only home-mask trial nor a comparison of PBM against no treatment. [7]

Likewise, an outcome from a pigment-targeting laser, intense pulsed light (IPL) or photodynamic therapy cannot be transferred to an ordinary LED mask. The term “light treatment” is too broad to establish equivalence.

Heat is a question to measure, not an explanation to assume

“The mask got warm” does not tell you its skin-surface temperature, spectral output or delivered light exposure. Near-infrared light is also not interchangeable with an infrared heating treatment. A device's optical settings and its thermal behavior need separate documentation.

The sources reviewed here do not establish a universal temperature threshold at which home LED exposure worsens melasma. They also do not establish that warmth explains every report of darkening. It would be equally unsupported to promise that any device described as “nonthermal” cannot cause pigment change.

For a meaningful device review, ask whether skin-temperature measurements exist for the intended mode and fit, how they were measured, and whether pigment outcomes were tracked. Those are unanswered evidence questions when measurements are missing—not permission to experiment with longer exposure.

Why improvement—or worsening—after a mask is hard to interpret

Sun exposure, pregnancy-related hormonal changes and some medicines can influence melasma. If one changes while a person starts LED use, timing alone cannot identify the cause of a pigment change. [8] Skin-care irritation adds another complication: the American Academy of Dermatology (AAD) notes that products that burn or sting can darken spots. [9]

Anecdotes deserve attention as reports of a problem; they cannot tell us how often it happens or which wavelength caused it. A before-and-after image also becomes difficult to interpret when lighting, camera exposure, makeup or the treatment plan changes.

If you notice a change, record the date, exact device and mode, actual use, skin symptoms and concurrent treatment or sun-exposure changes for your clinician. Photos taken under consistent conditions can document appearance, but they do not replace examination or a controlled study. Do not deliberately repeat a suspected reaction to test the theory.

Photoprotection still matters

AAD melasma guidance recommends daily sun protection and tinted sunscreen containing iron oxide to address visible light, alongside SPF 30 or higher. This is outdoor photoprotection advice. It is not a method for making an unverified LED exposure safe, and it does not authorize using a mask over sunscreen. Follow the exact device's skin-preparation instructions. [9]

What to review before changing your exposure

Bring the device instructions and any complete clinical study to a dermatologist. The following questions make the discussion more useful:

1. Diagnosis: Is the concern confirmed melasma, another pigmentary condition or a mixture?
2. Light identity: Which wavelengths operate in this mode? Are red, blue and near-infrared delivered together or separately?
3. Actual exposure: Is irradiance documented at the intended treatment position? Are geometry, pulse settings and temperature behavior described?
4. Study match: Did the research study diagnosed melasma and comparable skin types using this device or a justified equivalent?
5. Attribution: Was there a suitable control, and were other therapies and photoprotection handled consistently?
6. Outcomes: Were melasma severity, worsening, irritation and recurrence measured—not just satisfaction or general brightness?
7. Personal context: How do your current medicines, skin-care treatments and history of reactions affect suitability?

There is no melasma-specific universal schedule established by this evidence audit. Copying a study's minutes without its light output, spectrum and setup does not reproduce the intervention. Missing instructions or incomplete technical information leave suitability unresolved.

Three claims to treat cautiously

• “It fades spots, so it treats melasma.” Verify the diagnosis and measured endpoint before accepting that transfer.
• “Blue is risky, so red is always safe.” A result for one spectrum does not establish the safety of another exposure.
• “The combination worked, so the LED worked.” Shared background treatment prevents that conclusion without an appropriate comparison.

FAQ

Can a wrinkle study tell me whether melasma will improve?

No. Even a well-designed wrinkle trial needs separate melasma-specific outcomes to answer that question. Improvement in texture or fine lines is not evidence of pigment control.

Should I switch to red-only mode if a mixed mode caused darkening?

A color switch is not a validated remedy for an unexplained reaction. Pause and review what happened rather than using a different mode as a self-directed rechallenge. The actual spectrum and your diagnosis still need checking.

Can I cover melasma patches and treat the rest of my face?

An improvised covering is not a verified shielding method or a validated partial-face protocol. It can also change the device's fit. Ask about the exact device and intended treatment area before modifying the setup.

Does an absence of reported pigment reactions prove safety?

No. Ask whether the study actively measured darkening, included relevant skin types and followed participants long enough to capture recurrence. A small study with no reported events cannot establish zero risk for all users.

The next step is a better evidence match

For melasma, an LED's color name is not enough. The useful evidence connects a confirmed diagnosis, a defined exposure, an appropriate comparison and pigment-specific follow-up. Until that match is established, neither a benefit claim nor a pigment-safety guarantee is justified for an unspecified home device.